Developer site: The content shown here is test data.

Health Dictionary AI Health Chat Find an Online Doctor
A serene Zen garden with raked sand and smooth stones, symbolising clarity and calm

Health Dictionary

Back to skin conditions

Pheochromocytoma screening

Introduction

Overview

Overview

Familial pheochromocytoma is associated with multiple endocrine neoplasias, VHL and neurofibromatosis1 and should be screened by plasma fractionated metanephrines levels. The next step is to obtain 24-hour urinary fractionated metanephrine levels. Imaging should be considered if the initial tests are positive. Genetic testing also should be performed in high-risk patients.

Screening

Screening

Biochemical screening

  • According to the Endocrine Society, biochemical screening for pheochromocytoma in recommended among patients with:
    • VHL syndrome– started at 5 years of age with biochemical surveillance every year for the rest of life.
    • Signs or symptoms suggesting catecholamine excess, especially if the symptoms are paroxysmal.
    • Unexpected blood pressure changes to drugs, surgery, or anesthesia
    • Unexplained blood pressure variability
    • Incidentaloma, even if the patient is normotensive
    • Blood pressure that is difficult to control
    • History of previous treatment for pheochromocytoma or paraganglioma
    • Hereditary risk of pheochromocytoma or paraganglioma in family members
    • Syndromic features relating to a pheochromocytoma-related hereditary syndromes [1]
  • Plasma fractionated metanephrine level is the best test. If elevated, 24-hour urinary fractionated metanephrines should be done.

Imaging screening

Anatomic imaging should be used when norepinephrine levels are elevated more than two times upper normal limits.[2]

  • For high-risk children, screening for pheochromocytoma should begin by 11 years of age.
  • For moderate risk patients, screening should be started by 16 years of age.
  • If positive, adrenal imaging (CT) or (MRI) should be performed.

Genetic screening

References

References

  1. ↑ 1.0 1.1 Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH; et al. (2014). “Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline”. J Clin Endocrinol Metab. 99 (6): 1915–42. doi:10.1210/jc.2014-1498. PMID 24893135.
  2. ↑ Aufforth RD, Ramakant P, Sadowski SM, Mehta A, Trebska-McGowan K, Nilubol N; et al. (2015). “Pheochromocytoma Screening Initiation and Frequency in von Hippel-Lindau Syndrome”. J Clin Endocrinol Metab. 100 (12): 4498–504. doi:10.1210/jc.2015-3045. PMC 4667160. PMID 26451910.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohammed Abdelwahed M.D[2]